Ultragenyx Pharmaceutical (NASDAQ:RARE) released its earnings results on Thursday. The biopharmaceutical company reported ($1.62) EPS for the quarter, missing analysts’ consensus estimates of ($1.61) by ($0.01), Bloomberg Earnings reports. Ultragenyx Pharmaceutical had a negative net margin of 470.18% and a negative return on equity of 52.16%. The business had revenue of $35.59 million for the quarter, compared to the consensus estimate of $32.31 million.
Shares of NASDAQ RARE traded down $1.90 during trading hours on Friday, reaching $61.00. The stock had a trading volume of 33,023 shares, compared to its average volume of 586,843. Ultragenyx Pharmaceutical has a 52-week low of $35.41 and a 52-week high of $74.50. The firm has a market cap of $3.63 billion, a price-to-earnings ratio of -8.42 and a beta of 2.35. The business’s fifty day moving average price is $53.58 and its two-hundred day moving average price is $47.87. The company has a current ratio of 6.79, a quick ratio of 6.64 and a debt-to-equity ratio of 0.04.
A number of equities research analysts recently issued reports on RARE shares. Wedbush raised their price target on Ultragenyx Pharmaceutical from $71.00 to $75.00 and gave the stock an “outperform” rating in a research note on Friday. SunTrust Banks reaffirmed a “buy” rating and issued a $80.00 price objective (up previously from $75.00) on shares of Ultragenyx Pharmaceutical in a research report on Friday, January 10th. ValuEngine lowered Ultragenyx Pharmaceutical from a “buy” rating to a “hold” rating in a research note on Tuesday, October 29th. Raymond James downgraded Ultragenyx Pharmaceutical from an “outperform” rating to a “market perform” rating in a research report on Thursday, January 2nd. Finally, Morgan Stanley lifted their target price on Ultragenyx Pharmaceutical from $73.00 to $77.00 and gave the stock an “overweight” rating in a research report on Friday, January 17th. Four research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. Ultragenyx Pharmaceutical currently has a consensus rating of “Buy” and an average price target of $74.83.
Ultragenyx Pharmaceutical Company Profile
Ultragenyx Pharmaceutical, Inc is a biopharmaceutical company, which engages in the identification, acquisition, development and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. Its product includes Mepsevii and Crysvita. The company was founded by Emil D.
Featured Story: What are no-load funds?
Receive News & Ratings for Ultragenyx Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.